We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Results 1 to 5 of 16
Most popular |Most recent


Obviousness central to Federal Court’s REYATAZ (atazanavir bisulfate) decision

Canada - June 24 2016 In a decision dated May 27, 2016 in respect of Bristol-Myers Squibb’s (“BMS”) REYATAZ (atazanavir bisulfate), Justice Mactavish of the Federal...


Federal Court of Appeal affirms application of principles of causation, burden of proof and laws of evidence to section 8 proceedings

Canada - June 6 2016 In its recent decision, reported as Pfizer Canada Inc. v Teva Canada Limited, 2016 FCA 161, the Federal Court of Appeal ("FCA") overturned the...

Patrick Cashin.


Competition Bureau releases guidelines in respect of settlements under the PM(NOC) Regulations

Canada - April 8 2016 On March 31, 2016, the Competition Bureau released its updated Intellectual Property Enforcement Guidelines (the "IPEGs"). The updated IPEGs replace...

François Baril.


Federal court holds that post-filing amendments are subject to data protection provisions

Canada - November 19 2015 In Hospira Healthcare Corporation v Canada (Minister of Health) (2015 FC 1205), Justice Gagné of the Federal Court dismissed Hospira’s application...


Federal court issues first biologics decision under PM(NOC) Regulations

Canada - November 17 2015 Amgen Canada Inc v Apotex Inc(2015 FC 1261) is the first decision of the Federal Court under the Patented Medicines (Notice of Compliance)...